According to filings with the U.S. Securities and Exchange Commission, SetPoint Medical is raising up to $114,999,987.54 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About SetPoint Medical
SetPoint Medical is a privately held clinical-stage healthcare company dedicated to treating patients with autoimmune diseases. The company is developing a novel platform designed to stimulate the vagus nerve to activate innate anti-inflammatory pathways to produce a systemic immune-restorative effect. SetPoint Medicals platform technology is designed to offer patients and providers a treatment alternative for rheumatoid arthritis, inflammatory bowel disease, and other chronic autoimmune conditions with potentially less risk and cost than drug therapy.

To learn more about SetPoint Medical, visit http://setpointmedical.com/
SetPoint Medical Linkedin Page: https://www.linkedin.com/company/setpoint-medical/

Contact:
Murthy Simhambhatla, Chief Executive Officer
661-750-6140
https://www.linkedin.com/in/murthy-simhambhatla-884668bb/

SOURCE: http://www.intelligence360.io
Copyright (c) 2025 SI360 Inc. All rights reserved.